GliomaBRAIN MATRIXNCT04274283
Tessa Jowell BRAIN MATRIX - Platform Study
An observational study of Glioma, run by University of Birmingham at 14 sites in United Kingdom.
Trial summary
The main aim of the Tessa Jowell BRAIN MATRIX - Platform Study is to more precisely determine the exact type of tumour patients have by developing the essential infrastructure to provide rapid and accurate molecular diagnosis. Read more about this study
- Who is it for?
- Ages 16 years and older
- Conditions the study is for
- Glioma
- What is being tested?
- Matched Tumour and Blood Sample - Research Pathway and Matched Tumour and Blood Sample - NHS GMS pathway
- How many people
- 1,000 participants
- Where
- 14 sitesUnited Kingdom
- Study dates
- 24 Nov 2020to Feb 2028
- How long will I take part?
- 5 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: * Patients with a newly diagnosed suspected WHO Grade 2-4 glioma, (as evidenced radiologically) AND suitable for a diagnostic or therapeutic surgical procedure resulting in a frozen tumour sample matched to a blood sample. * Patients with progression with known WHO Grade 2-4 glioma (those with available frozen tumour will be prioritised for detailed genomic analysis).
Who may be able to join
- Newly diagnosed suspected WHO Grade 2-4 glioma, (as evidenced radiologically) AND suitable for a diagnostic or therapeutic surgical procedure resulting in a tumour sample matched to a blood sample.
- Patients with progression with known WHO Grade 2-4 glioma (those with available frozen tumour will be prioritised for detailed genomic analysis).
- Valid written informed consent for the study.
Who cannot join
- Primary spinal cord tumours
- Active treatment of other malignancy
- Contraindication to MRI
- Patients without standard of care imaging available
Trial locations and contacts
14 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Joshua Savage contact
14 sites in 1 country
United Kingdom14 sites, 11 recruiting
- Recruiting
Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust
Birmingham, B15 2TH
Victoria Wykes
- Terminated
Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust
Cambridge, CB2 0QQ
- Recruiting
Velindre Cancer Centre, Velindre University NHS Trust
Cardiff, CF14 2TL
Jillian Maclean
- Active, not recruiting
NHS Lothian
Edinburgh, EH4 2XU
- Active, not recruiting
Queen Elizabeth Unviersity Hospital, NHS Greater Glasgow and Clyde Health Board
Glasgow, G51 4TF
- Recruiting
St James's University Hospital, Leeds Teaching Hospitals NHS Trust
Leeds, LS9 7TF
Ryan Mathew
- Recruiting
The Walton Centre, The Walton Centre NHS Foundation Trust
Liverpool, L9 7LJ
Michael Jenkinson
- Recruiting
King's College Hospital, King's College Hospital NHS Foundation Trust
London, SE5 9RS
Keyoumars Ashkan
- Recruiting
Charing Cross Hospital, Imperial College Healthcare NHS Trust
London, W6 8RF
Matthew Williams
- Recruiting
The Christie Hospital, The Christie NHS Foundation Trust
Manchester, M20 4BX
Catherine McBain
- Recruiting
Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust
Manchester, M6 8HD
David Coope
- Recruiting
Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust
Newcastle upon Tyne, NE7 7DN
Joanne Lewis
- Recruiting
Queen's Medical Centre, Nottingham University Hospitals NHS Trust
Nottingham, NG7 2UH
Stuart Smith
- Recruiting
Churchill Hospital, Oxford University Hospitals NHS Foundation Trust
Oxford, OX3 9DU
Meera Nandhabalan
About this study
Official title: A British Feasibility Study of Molecular Stratification and Targeted Therapy to Optimize the Clinical Management of Patients With Glioma by Enhancing Clinical Outcomes, Reducing Avoidable Toxicity, Improving Management of Post-operative Residual & Recurrent Disease and Improving Survivorship
The main aim of the Tessa Jowell BRAIN MATRIX - Platform Study is to more precisely determine the exact type of tumour patients have by developing the essential infrastructure to provide rapid and accurate molecular diagnosis. A large network of clinical hubs across the United Kingdom, with expertise in managing patients with brain tumours, will be developed. Once established this infrastructure will facilitate the rapid introduction of clinical trials testing targeted therapies tailored to the genetic changes of an individual's tumour.
Read the detailed description
Gliomas, a type of brain tumour, are the most common primary tumour of the central nervous system (CNS) and in 2016 there were 5250 deaths from brain tumours in the UK. However, brain tumours are a challenging disease to treat. The tumour's location within the brain and its tendency to grow into nearby brain tissue often make it very difficult to remove the tumour completely with surgery. There is also difficulty in delivering drugs in adequate amounts to the tumour due to the natural defences of the brain.
Brain tumours arise due to changes in the DNA and other molecules in cells of the brain. Different types of gliomas can have different changes and these can be used to determine a precise 'molecular diagnosis'. The ultimate goal for the Tessa Jowell BRAIN MATRIX is to learn how to use these molecular changes to more precisely determine what exact type of tumour patients have, and to identify, decide and test whether specific 'targeted' treatments could improve the survival and/or quality of life of patients with brain tumours.
Tessa Jowell BRAIN MATRIX is a programme of work, the principal purpose of which is to improve the knowledge of, and treatment for, glioma. The programme will include a Platform Study and subsequent interventional clinical trials. The Tessa Jowell BRAIN MATRIX Platform Study forms the backbone of this programme. In the Platform Study, the aim is to develop the infrastructure to provide rapid and accurate molecular diagnosis and the infrastructure to deliver clinical trials of new therapies in the future, thereby improving clinical outcomes in brain tumours.
The researchers aim to recruit 1,000 patients to the study. As gliomas occur at all ages and their specific subtype is hard to predict pre-operatively, the patient population eligible for the study is broad. A large network of clinical hubs across the UK, with expertise in managing patients with brain tumours, will be developed. Once established this infrastructure will facilitate the rapid introduction of clinical trials testing targeted therapies tailored to the genetic changes of an individual's tumour.
Eligible patients will either have had, or be about to have, surgery for their tumour. As part of this study, tumour removed during the operation will be analysed to look for specific molecular changes. As with normal standard care, the tumour will be analysed by a local pathologist. A small part will be sent for review by experts and advanced molecular analysis will be undertaken to get a detailed understanding of the DNA/molecular changes within the patient's tumour. These results will be fed back to the patient's treating doctor. It is intended that this will occur within 28 days; however, it may be longer while the study becomes fully operational.
If samples are available from a patient's previous surgery to their tumour, these may also be analysed. Similarly, if available, other relevant samples such as cerebrospinal fluid, collected as part of their care, may also be analysed. In addition, as technologies and analyses improve the understanding of brain tumours, the researchers may find important results at a later date. These will be fed back to the patient's doctor. Patients will also be asked to give a blood sample, which will also be analysed to look at the molecular features, including of their DNA. This is required to identify what 'new' changes have occurred in the patient's tumour. Following surgery, patients will continue with other treatment(s) as directed by their doctor.
Treatment generally involves radiotherapy and chemotherapy. As is standard practice, patients will be closely monitored for signs of disease progression and the effects of the treatment given. As part of this study, information on patients' treatments and disease will be collected.
Images from brain scans patients undergo, along with relevant clinical information, will also be sent to and stored by the University of Edinburgh, and where appropriate, undergo expert review by a panel of radiologists with expertise in brain tumours. If patients have further surgery, some of the tissue removed may also be analysed.
- Conditions
- Glioma
- Being tested
- Matched Tumour and Blood Sample - Research Pathway, Matched Tumour and Blood Sample - NHS GMS pathway
- Medical subject headings
- Glioma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Matched Tumour and Blood Sample - Research PathwayOther
For patient's undergoing surgery fresh tissue will be collected from the initial surgery and frozen until shipment to the Oxford BRAIN MATRIX Lab. Matched blood sample for germline DNA will be taken post-Platform Study entry. For patients with progression with available tumour samples from previous tumour surgery, blood will be collected and sent to Oxford along with their tumour samples.
Samples will be shipped together to Oxford for molecular analysis (Whole Genome Sequencing (WGS) and EPIC array). The BRAIN MATRIX neuropathology and genomics team will produce an integrated report (histology, WGS, Heidelberg Classifier) for each case in consultation with the local neuropathology team. Once data is available, a virtual MDT with the BRAIN MATRIX neuropathology, genomics team and local site will be held to ensure all relevant information is incorporated in the final BRAIN MATRIX diagnostic report. The resulting integrated histological-molecular report will be available to local sites
Matched Tumour and Blood Sample - NHS GMS pathwayOther
Tessa Jowell BRAIN MATRIX centres in England can submit matched tissue and blood samples for Whole Genome Sequencing through the standard of care NHS Genomic Medicine Service pathway via their Genomic Laboratory Hub. For those from Devolved Nations, samples must go to the Oxford BRAIN MATRIX Laboratory who can facilitate the processing of samples through an alternative NHS GMS GLH or via the research pathway.
What is being measured
The primary outcome is the main question the study is designed to answer.
Time (from biopsy) to integrated histological-molecular diagnosis using standard-of-care NHS practice
This is defined as the difference (days) between date of biopsy and date of final local pathology report.
Measured: 28 days
Time (from biopsy) to WGS report to the treating clinician using NHS Genomic Medicine Service
This is defined at the difference (days) between date of biopsy and date that a patient's Genomic Tumour Advisory Board (GTAB) report is produced.
Measured: 28
Secondary outcomes (15)
Time to completion of each node of tissue and imaging pathway
The time to each node of the pathway will be measured from the date of receipt at the current node to date of delivery at the next.
Measured: To be achieved within a timescale of up to 5 years
Tumour and biological sample(s) quality control status
Tumour and biological sample collection will be measured against protocol guidelines. These data will be collected in the surgical and pathological forms.
Measured: To be achieved within a timescale of up to 5 years
Imaging quality control status
Imaging will be measured against established clinical guideline. The imaging form will measure compliance against these guidelines.
Measured: To be achieved within a timescale of up to 5 years
Inter-rater agreement of Response Assessment in Neuro-Oncology (RANO) assessments
Scans will be assessed and scored according to RANO criteria by the hub of Neuro-radiologists.
Measured: To be achieved within a timescale of up to 5 years
Extent of surgical resection
Evaluated from the post-operative MRI scan and categorised as follows: Closed biopsy, open biopsy, debulking <50%, subtotal resection 50-90%, near total resection 90-<100%, gross total resection 100%.
Measured: To be achieved within a timescale of up to 5 years
Overall survival time
Defined as the time from date of diagnosis to the date of death. Patients who are alive at the time of analysis will be censored at the date last seen in clinic.
Measured: To be achieved within a timescale of up to 5 years
Intracranial progression-free survival time
Defined as the time from date of registration to the earliest of date of intracranial progressive disease or death from disease. The date of an event is defined as the earliest confirmation of progression by radiological assessment, clinical symptoms or MDT. Patients without progression at the time of analysis will be censored at the date last seen in clinic.
Measured: To be achieved within a timescale of up to 5 years
Quality of Life (QoL) scores
Longitudinal measures of QoL will be generated from the QoL questionnaire according to the questionnaire-specific algorithm for scoring.
Measured: To be achieved within a timescale of up to 5 years
Type of interventions received
Details of the type of interventions received will be monitored throughout the follow-up period and recorded on the Case Report Form.
Measured: To be achieved within a timescale of up to 5 years
Type of complications from treatments (standard of care) received.
Details of complications relating to standard of care treatments received will be monitored throughout the follow-up period and recorded on the Case Report Form.
Measured: To be achieved within a timescale of up to 5 years
Concordance of diagnoses
In relation to initial local radiological diagnosis, local pathological diagnosis and integrated histological-molecular diagnosis, any difference between the tiers of diagnoses will be highlighted and categorised as: discordant; agreed; refined.
Measured: To be achieved within a timescale of up to 5 years
Samples and images centrally stored
Defined as confirmed central storage of images and material.
Measured: To be achieved within a timescale of up to 5 years
Targetable mutation(s) identified
Relevant targetable mutations identified by Whole Genome Sequencing and Epigenomic Classification.
Measured: To be achieved within a timescale of up to 5 years
Post-mortem sampling consent status and sample collection confirmation
Based on receipt of post-mortem consent form, and on post-mortem samples with confirmed central storage.
Measured: To be achieved within a timescale of up to 5 years
Number of applications to, and outputs resulting from data repository
As per title.
Measured: To be achieved within a timescale of up to 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Feb 2020
- Study start24 Nov 2020
- Primary completionFeb 2027 (estimated)
- Study completionFeb 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for GliomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,000 participants (estimated)
- Target duration
- 5 Years
Sponsor and investigators
- Lead sponsor
- University of Birmingham
- Sponsor type
- University, hospital or other
- Collaborators
- The Brain Tumour Charity, University of Oxford, University of Edinburgh, Genomics England
- Responsible party
- Sponsor
- Investigators
- Colin Watts, Principal investigator, Unviersity of Birmingham
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04274283
- Sponsor's protocol ID
- RG_18-258
- Other IDs
- 14218060
- Acronym
- BRAIN MATRIX
- Status last verified
- Apr 2026
- First submitted
- 14 Feb 2020
- Last updated
- 5 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Scientifically sound proposals from appropriately qualified researchers will be considered for data sharing. Requests should be made by returning a Data Sharing Request Form to newbusiness@trials.bham.ac.uk; this captures the research requirements, statistical analysis plan, and intended publication schedule. Requests will be reviewed by the Cancer Research UK Clinical Trials Unit (CRCTU) Directors in discussion with the Chief Investigator (CI), Study Management Group (SMG) and independent Scientific Advisory Board (SAB). They will consider the scientific validity of the request, qualifications of the researchers, CI, SMG \& SAB views, consent arrangements, practicality of anonymizing the requested data \& contractual obligations. If supportive of the request, and where not already obtained, Sponsor consent for data transfer will be sought before notifying applicants of the outcome. It is anticipated that applicants will be notified within 3 months of receipt of the original request.
Publications
Watts C, Savage J, Patel A, Mant R, Wykes V, Pohl U, Bulbeck H, Apps J, Sharpe R, Thompson G, Waldman AD, Ansorge O, Billingham L; TJBM Investigators. Protocol for the Tessa Jowell BRAIN MATRIX Platform Study. BMJ Open. 2022 Sep 8;12(9):e067123. doi: 10.1136/bmjopen-2022-067123.
PubMed 36378622
Study at a glance
From the registry record, last updated by the sponsor on 5 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A British Feasibility Study of Molecular Stratification and Targeted Therapy to Optimize the Clinical Management of Patients With Glioma by Enhancing Clinical Outcomes, Reducing Avoidable Toxicity, Improving Management of Post-operative Residual & Recurrent Disease and Improving Survivorship
- ClinicalTrials.gov ID
- NCT04274283
- Acronym / sponsor ID
- BRAIN MATRIX / RG_18-258
- Conditions
- Glioma
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- University of BirminghamUniversity, hospital or other
- Collaborators
- The Brain Tumour Charity, University of Oxford, University of Edinburgh, Genomics England
- Study start
- 24 Nov 2020 (actual)
- Primary completion
- Feb 2027 (estimated)
- Study completion
- Feb 2028 (estimated)
- First posted
- 18 Feb 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main aim of the Tessa Jowell BRAIN MATRIX - Platform Study is to more precisely determine the exact type of tumour patients have by developing the essential infrastructure to provide rapid and accurate molecular diagnosis. A large network of clinical hubs across the United Kingdom, with expertise in managing patients with brain tumours, will be developed. Once established this infrastructure will facilitate the rapid introduction of clinical trials testing targeted therapies tailored to the genetic changes of an individual's tumour.
Detailed description
Gliomas, a type of brain tumour, are the most common primary tumour of the central nervous system (CNS) and in 2016 there were 5250 deaths from brain tumours in the UK. However, brain tumours are a challenging disease to treat. The tumour's location within the brain and its tendency to grow into nearby brain tissue often make it very difficult to remove the tumour completely with surgery. There is also difficulty in delivering drugs in adequate amounts to the tumour due to the natural defences of the brain.
Brain tumours arise due to changes in the DNA and other molecules in cells of the brain. Different types of gliomas can have different changes and these can be used to determine a precise 'molecular diagnosis'. The ultimate goal for the Tessa Jowell BRAIN MATRIX is to learn how to use these molecular changes to more precisely determine what exact type of tumour patients have, and to identify, decide and test whether specific 'targeted' treatments could improve the survival and/or quality of life of patients with brain tumours.
Tessa Jowell BRAIN MATRIX is a programme of work, the principal purpose of which is to improve the knowledge of, and treatment for, glioma. The programme will include a Platform Study and subsequent interventional clinical trials. The Tessa Jowell BRAIN MATRIX Platform Study forms the backbone of this programme. In the Platform Study, the aim is to develop the infrastructure to provide rapid and accurate molecular diagnosis and the infrastructure to deliver clinical trials of new therapies in the future, thereby improving clinical outcomes in brain tumours.
The researchers aim to recruit 1,000 patients to the study. As gliomas occur at all ages and their specific subtype is hard to predict pre-operatively, the patient population eligible for the study is broad. A large network of clinical hubs across the UK, with expertise in managing patients with brain tumours, will be developed. Once established this infrastructure will facilitate the rapid introduction of clinical trials testing targeted therapies tailored to the genetic changes of an individual's tumour.
Eligible patients will either have had, or be about to have, surgery for their tumour. As part of this study, tumour removed during the operation will be analysed to look for specific molecular changes. As with normal standard care, the tumour will be analysed by a local pathologist. A small part will be sent for review by experts and advanced molecular analysis will be undertaken to get a detailed understanding of the DNA/molecular changes within the patient's tumour. These results will be fed back to the patient's treating doctor. It is intended that this will occur within 28 days; however, it may be longer while the study becomes fully operational.
If samples are available from a patient's previous surgery to their tumour, these may also be analysed. Similarly, if available, other relevant samples such as cerebrospinal fluid, collected as part of their care, may also be analysed. In addition, as technologies and analyses improve the understanding of brain tumours, the researchers may find important results at a later date. These will be fed back to the patient's doctor. Patients will also be asked to give a blood sample, which will also be analysed to look at the molecular features, including of their DNA. This is required to identify what 'new' changes have occurred in the patient's tumour. Following surgery, patients will continue with other treatment(s) as directed by their doctor.
Treatment generally involves radiotherapy and chemotherapy. As is standard practice, patients will be closely monitored for signs of disease progression and the effects of the treatment given. As part of this study, information on patients' treatments and disease will be collected.
Images from brain scans patients undergo, along with relevant clinical information, will also be sent to and stored by the University of Edinburgh, and where appropriate, undergo expert review by a panel of radiologists with expertise in brain tumours. If patients have further surgery, some of the tissue removed may also be analysed.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 5 Years
Who may qualify
- Ages
- 16 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- * Patients with a newly diagnosed suspected WHO Grade 2-4 glioma, (as evidenced radiologically) AND suitable for a diagnostic or therapeutic surgical procedure resulting in a frozen tumour sample matched to a blood sample. * Patients with progression with known WHO Grade 2-4 glioma (those with available frozen tumour will be prioritised for detailed genomic analysis).
Key inclusion criteria (3 listed)
- Newly diagnosed suspected WHO Grade 2-4 glioma, (as evidenced radiologically) AND suitable for a diagnostic or therapeutic surgical procedure resulting in a tumour sample matched to a blood sample.
- Patients with progression with known WHO Grade 2-4 glioma (those with available frozen tumour will be prioritised for detailed genomic analysis).
- Valid written informed consent for the study.
Key exclusion criteria (4 listed)
- Primary spinal cord tumours
- Active treatment of other malignancy
- Contraindication to MRI
- Patients without standard of care imaging available
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Matched Tumour and Blood Sample - Research PathwayFor patient's undergoing surgery fresh tissue will be collected from the initial surgery and frozen until shipment to the Oxford BRAIN MATRIX Lab. Matched blood sample for germline DNA will be taken post-Platform Study entry. For patients with progression with available tumour samples from previous tumour surgery, blood will be collected and sent to Oxford along with their tumour samples. Samples will be shipped together to Oxford for molecular analysis (Whole Genome Sequencing (WGS) and EPIC array). The BRAIN MATRIX neuropathology and genomics team will produce an integrated report (histology, WGS, Heidelberg Classifier) for each case in consultation with the local neuropathology team. Once data is available, a virtual MDT with the BRAIN MATRIX neuropathology, genomics team and local site will be held to ensure all relevant information is incorporated in the final BRAIN MATRIX diagnostic report. The resulting integrated histological-molecular report will be available to local sites | Other | – |
| Matched Tumour and Blood Sample - NHS GMS pathwayTessa Jowell BRAIN MATRIX centres in England can submit matched tissue and blood samples for Whole Genome Sequencing through the standard of care NHS Genomic Medicine Service pathway via their Genomic Laboratory Hub. For those from Devolved Nations, samples must go to the Oxford BRAIN MATRIX Laboratory who can facilitate the processing of samples through an alternative NHS GMS GLH or via the research pathway. | Other | – |
Primary outcome
Time (from biopsy) to integrated histological-molecular diagnosis using standard-of-care NHS practice
Time frame: 28 days
This is defined as the difference (days) between date of biopsy and date of final local pathology report.
Time (from biopsy) to WGS report to the treating clinician using NHS Genomic Medicine Service
Time frame: 28
This is defined at the difference (days) between date of biopsy and date that a patient's Genomic Tumour Advisory Board (GTAB) report is produced.
15 secondary outcomes
Time to completion of each node of tissue and imaging pathway
Time frame: To be achieved within a timescale of up to 5 years
Tumour and biological sample(s) quality control status
Time frame: To be achieved within a timescale of up to 5 years
Imaging quality control status
Time frame: To be achieved within a timescale of up to 5 years
Inter-rater agreement of Response Assessment in Neuro-Oncology (RANO) assessments
Time frame: To be achieved within a timescale of up to 5 years
Extent of surgical resection
Time frame: To be achieved within a timescale of up to 5 years
Overall survival time
Time frame: To be achieved within a timescale of up to 5 years
Intracranial progression-free survival time
Time frame: To be achieved within a timescale of up to 5 years
Quality of Life (QoL) scores
Time frame: To be achieved within a timescale of up to 5 years
Type of interventions received
Time frame: To be achieved within a timescale of up to 5 years
Type of complications from treatments (standard of care) received.
Time frame: To be achieved within a timescale of up to 5 years
Concordance of diagnoses
Time frame: To be achieved within a timescale of up to 5 years
Samples and images centrally stored
Time frame: To be achieved within a timescale of up to 5 years
Targetable mutation(s) identified
Time frame: To be achieved within a timescale of up to 5 years
Post-mortem sampling consent status and sample collection confirmation
Time frame: To be achieved within a timescale of up to 5 years
Number of applications to, and outputs resulting from data repository
Time frame: To be achieved within a timescale of up to 5 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 May 2026.
- Background: PubMed 36378622Watts C, Savage J, Patel A, Mant R, Wykes V, Pohl U, Bulbeck H, Apps J, Sharpe R, Thompson G, Waldman AD, Ansorge O, Billingham L; TJBM Investigators. Protocol for the Tessa Jowell BRAIN MATRIX Platform Study. BMJ Open. 2022 Sep 8;12(9):e067123. doi: 10.1136/bmjopen-2022-067123.
- Trial WebsiteLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. Scientifically sound proposals from appropriately qualified researchers will be considered for data sharing. Requests should be made by returning a Data Sharing Request Form to newbusiness@trials.bham.ac.uk; this captures the research requirements, statistical analysis plan, and intended publication schedule. Requests will be reviewed by the Cancer Research UK Clinical Trials Unit (CRCTU) Directors in discussion with the Chief Investigator (CI), Study Management Group (SMG) and independent Scientific Advisory Board (SAB). They will consider the scientific validity of the request, qualifications of the researchers, CI, SMG \& SAB views, consent arrangements, practicality of anonymizing the requested data \& contractual obligations. If supportive of the request, and where not already obtained, Sponsor consent for data transfer will be sought before notifying applicants of the outcome. It is anticipated that applicants will be notified within 3 months of receipt of the original request.
Related trials for Glioma
Active, not recruitingPhase 2
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)
Optic Pathway Glioma
Not yet recruitingPhase 1
Study of Disulfiram to Reduce Myeloid Immunosuppression and Steroid Dependence in Resectable High Grade Glioma
Brain (Nervous System) Cancers
Active, not recruitingPhase 2/3
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Glioblastoma, Gliosarcoma
RecruitingPhase 1/2
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
MTAP-deleted Solid Tumors
Enrolling by invitationPhase 1
Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma
Glioblastoma (GBM), Diffuse Midline Glioma (DMG)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Joshua Savage contact
Colin Watts principal investigator
Unviersity of Birmingham
14 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Glioma, run by University of Birmingham at 14 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 14 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Rhys Mant (0121 414 6788, brainmatrix@trials.bham.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time (from biopsy) to integrated histological-molecular diagnosis using standard-of-care NHS practice (time frame: 28 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04274283, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 May 2026.